Article
Tight-control or treat-to-target (T2T) strategy is advocated in several diseases, but the recent TICOSPA trial in axial spondyloarthritis (axSpA) showed that T2T was not superior to usual care (UC).
All News
Dr. John Cush
Tweet
Kikuchi’s Dz (AKA Kikuchi-Fujimoto dz) is rare, affects young women >men w/ recurrent necrotizing lymphadenitis (may assoc w/ SLE, MAS, TB); Sx included fever, flu-Sxs, Wt loss, night sweats, Hi CRP/LFTs, lymphopenia, uncommon arthritis, organomegaly https://t.co/LpEOgbcfpP
Dr. John Cush
Tweet
Risk of Herpes zoster from upadacitinib RCTs: UPA > ADA > ADA+MTX > MTX. 5306 RA pts, HZ/100 Pt-Yrs was 0.8 MTX mono; 1.1 ADA+MTX; 3.0 UPA 15 mg and 5.3 UPA 30 mg. 71% of UP HZ cases involved a single dermatome. Higher risk w/ prior HZ & Asians https://t.co/0QUvXmFrJ3
Dr. John Cush
Tweet
Are You a High or Low Glucocorticoid Prescriber?
https://t.co/QbJzlrVMiV https://t.co/dZgJPKjisx
Dr. John Cush
Tweet
EULAR has updated its recommendations (points to consider - PtC) for rheumatologists managing patients during COVID-19; now with 2 overarching principles and 12 PtC.
Read more on #RheumNow
https://t.co/Q422Sl5Csj
Dr. John Cush
Tweet
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj
Dr. John Cush
Tweet
New podcast titled Quackademia available for download.
https://t.co/Y6Pqko1tYm https://t.co/2IvMIfPBkr
Dr. John Cush
Tweet
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/1pnXJkoCOn
Dr. John Cush
Tweet
In case you missed it…
Still’s Disease Following COVID-19 Vaccination
Read more on #RheumNow
https://t.co/23R41Pydve https://t.co/a44cYIkc98
Dr. John Cush
Tweet
ICYMI: Hepatitis B Reactivation with Rituximab and Abatacept
A serologic study of rheumatoid arthritis patients shows that HBV reactivation is seen with rituximab, and less so with abatacept, especially in patients without HBsAb positivity.
https://t.co/l1qCrWCyZd
#RheumNow https://t.co/EUoWt9xGdB
Dr. John Cush
Tweet
In case you missed it:
FDA Approves Avacopan for ANCA-Associated Vasculitis
https://t.co/L7UwhYBaVY
#RheumNow https://t.co/HypjLMLwjU
Dr. John Cush
Tweet
ICYMI:
Triple DMARD Rx - MSH vs MLH (Lef). 136 active #RA pts given OL MTX/SSZ/HCQ vs MTX/HCQ/LEF. Equal efficacy (EULAR-Good) was seen at wk 12 (54% vs 59%) and wk 24 (65% vs 62%) - hence LEF substitution was noninferior. https://t.co/F5CGj0w7Bh https://t.co/OuDMgNIKTA
Eric Topol
Tweet
For best practices in managing the Delta wave, the US would have done well to consult Puerto Rico
US 26 cases/100,000 people, 19/100K hospitalized 57% vaccinated
PR 3 cases/100,000 people, 3/100K hospitalized, 68% vaccinated https://t.co/kqlXBlmYpu
Emilio Martin Mola
Tweet
This 15-day-old boy developed this rash, which was diagnosed with neonatal lupus; anti-Ro and anti-La Abs were present, in both, mother and child. The mother never had had symptoms suggesting SLE or any autoimmune disease. The rash healed after 45 days; the boy is doing great😍 https://t.co/fYB0IzE7kY
Dr. John Cush
Tweet
In case you missed it…a popular read.
Clinical Associations with Myositis Antibodies
Read the full article on #RheumNow
https://t.co/tzPU1scc8x https://t.co/pmmtmIuz31
Dr. John Cush
Tweet
New podcast titled Quackademia available for download.
https://t.co/Y6Pqko1tYm https://t.co/Hm22p70d5e
Dr. John Cush
Tweet
Still’s Disease Following COVID-19 Vaccination
https://t.co/23R41Pydve https://t.co/y0loTQuKBH
Dr. John Cush
Tweet
Fluorosis presenting as lower back pain and stiffness of the neck, shoulders, hips, yellowish-brown tooth discoloration, LOM of Cx spine, hips, shoulders. Pelvic Xrays showed osteosclerosis without sacroiliitis. T scores were +12.1 LS spine, alk phos =479 https://t.co/t2lmoudUIM https://t.co/6dWH0Rqhva
Dr. John Cush
Tweet
CXCL13 predicts worse Xray status in early #RA. Study of 158 pts, followed 11-years. Baseline CXCL13 correlated with Xray progression (ΔTSS) at 11 years. CXCL13 was superior to CRP, DAS28CRP, SJC28, CCP predicting 11-yr Xray damage https://t.co/1WAdZoYQ1P
Dr. John Cush
Tweet
Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN
